{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:34:22Z","timestamp":1781202862262,"version":"3.54.1"},"reference-count":104,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Rett syndrome (RTT) and Rett-like syndromes [i.e., CDKL5 deficiency disorder (CDD) and FOXG1-syndrome] represent rare yet profoundly impactful neurodevelopmental disorders (NDDs). The severity and complexity of symptoms associated with these disorders, including cognitive impairment, motor dysfunction, seizures and other neurological features significantly affect the quality of life of patients and families. Despite ongoing research efforts to identify potential therapeutic targets and develop novel treatments, current therapeutic options remain limited. Here the potential of drug repurposing (DR) as a promising avenue for addressing the unmet medical needs of individuals with RTT and related disorders is explored. Leveraging existing drugs for new therapeutic purposes, DR presents an attractive strategy, particularly suited for neurological disorders given the complexities of the central nervous system (CNS) and the challenges in blood-brain barrier penetration. The current landscape of DR efforts in these syndromes is thoroughly examined, with partiuclar focus on shared molecular pathways and potential common drug targets across these conditions.<\/jats:p>","DOI":"10.3389\/fmed.2024.1425038","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T04:53:23Z","timestamp":1722228803000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Drug repurposing in Rett and Rett-like syndromes: a promising yet underrated opportunity?"],"prefix":"10.3389","volume":"11","author":[{"given":"Claudia","family":"Fuchs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A. C.","family":"\u2018t Hoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelieke R.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Ehrhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara D. M.","family":"Van Karnebeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/ejhg.2012.156","article-title":"The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy.","volume":"21","author":"Fehr","year":"2013","journal-title":"Eur J Hum Genet."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174176","article-title":"FOXG1-related syndrome: From clinical to molecular genetics and pathogenic mechanisms.","volume":"20","author":"Wong","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.93093","author":"Mao","year":"2020","journal-title":"Drug repurposing in neurological diseases: Opportunities and challenges: Drug repurposing - hypothesis, molecular aspects and therapeutic applications."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114239","article-title":"Drug repositioning: Progress and challenges in drug discovery for various diseases.","volume":"234","author":"Hua","year":"2022","journal-title":"Eur J Med Chem."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1352803","article-title":"Drug repurposing for rare: Progress and opportunities for the rare disease community.","volume":"11","author":"Jonker","year":"2024","journal-title":"Front Med (Lausanne)."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.20517\/rdodj.2023.22","article-title":"Bumetanide to treat autism spectrum disorders: Are complex administrative regulations fit to treat heterogeneous disorders?","volume":"3","author":"Ben-Ari","year":"2024","journal-title":"Rare Dis Orphan Drugs J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1007\/s10803-014-2144-4","article-title":"Brief report: An open-label study of the neurosteroid pregnenolone in adults with autism spectrum disorder.","volume":"44","author":"Fung","year":"2014","journal-title":"J Autism Dev Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41583-018-0006-3","article-title":"Rett syndrome: Insights into genetic, molecular and circuit mechanisms.","volume":"19","author":"Ip","year":"2018","journal-title":"Nat Rev Neurosci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/brain\/awy323","article-title":"Towards a better diagnosis and treatment of Rett syndrome: A model synaptic disorder.","volume":"142","author":"Banerjee","year":"2019","journal-title":"Brain."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0545-5","article-title":"Rett syndrome \u2013 biological pathways leading from MECP2 to disorder phenotypes.","volume":"11","author":"Ehrhart","year":"2016","journal-title":"Orphanet J Rare Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/6970190","article-title":"Cyclin-dependent kinase-like 5 (CDKL5): Possible cellular signalling targets and involvement in CDKL5 deficiency disorder.","volume":"2020","author":"Katayama","year":"2020","journal-title":"Neural Plast."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1042\/BST20220791","article-title":"CDKL5 deficiency disorder: Molecular insights and mechanisms of pathogenicity to fast-track therapeutic development.","volume":"50","author":"Van Bergen","year":"2022","journal-title":"Biochem Soc Trans."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.00035","article-title":"Transcription and beyond: Delineating FOXG1 function in cortical development and disorders.","volume":"14","author":"Hou","year":"2020","journal-title":"Front Cell Neurosci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"a009886","DOI":"10.1101\/cshperspect.a009886","article-title":"Synaptic Dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities.","volume":"4","author":"Zoghbi","year":"2012","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105856","article-title":"Synaptic genes and neurodevelopmental disorders: From molecular mechanisms to developmental strategies of behavioral testing.","volume":"173","author":"Michetti","year":"2022","journal-title":"Neurobiol Dis."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.813441","article-title":"Dysregulation of GABAergic signaling in neurodevelomental disorders: Targeting cation-chloride co-transporters to re-establish a proper E\/I balance.","volume":"15","author":"Cherubini","year":"2022","journal-title":"Front Cell Neurosci."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092169","article-title":"GABA and glutamate pathways are spatially and developmentally affected in the brain of mecp2-deficient mice.","volume":"9","author":"El-Khoury","year":"2014","journal-title":"PLoS One."},{"key":"B18","doi-asserted-by":"publisher","first-page":"E7287","DOI":"10.1073\/pnas.1615330113","article-title":"Jointly reduced inhibition and excitation underlies circuit-wide changes in cortical processing in Rett syndrome.","volume":"113","author":"Banerjee","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1073\/pnas.1524013113","article-title":"KCC2 rescues functional deficits in human neurons derived from patients with Rett syndrome.","volume":"113","author":"Tang","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0852-x","article-title":"KCC2 expression levels are reduced in post mortem brain tissue of Rett syndrome patients.","volume":"7","author":"Hinz","year":"2019","journal-title":"Acta Neuropathol Commun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.tips.2021.09.005","article-title":"Pharmacological tools to target NKCC1 in brain disorders.","volume":"42","author":"Savardi","year":"2021","journal-title":"Trends Pharmacol Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1212\/WNL.0000000000003352","article-title":"Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder.","volume":"87","author":"Fehr","year":"2016","journal-title":"Neurology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2019.02.015","article-title":"Cyclin-dependent kinase-like 5 deficiency disorder: Clinical review.","volume":"97","author":"Olson","year":"2019","journal-title":"Pediatr Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.resp.2013.06.022","article-title":"Breathing challenges in Rett syndrome: Lessons learned from humans and animal models.","volume":"189","author":"Ramirez","year":"2013","journal-title":"Respir Physiol Neurobiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.resp.2009.04.017","article-title":"Breathing disorders in Rett syndrome: Progressive neurochemical dysfunction in the respiratory network after birth.","volume":"168","author":"Katz","year":"2009","journal-title":"Respir Physiol Neurobiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.resp.2011.02.002","article-title":"The benzodiazepine Midazolam mitigates the breathing defects of Mecp2-deficient mice.","volume":"177","author":"Voituron","year":"2011","journal-title":"Respir Physiol Neurobiol."},{"key":"B27","author":"Germano","year":"2021","journal-title":"Congress paper AIRETT congress 2017"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1093\/cercor\/bhz114","article-title":"Loss of Foxg1 impairs the development of cortical SST-interneurons leading to abnormal emotional and social behaviors.","volume":"29","author":"Chen","year":"2019","journal-title":"Cereb Cortex."},{"key":"B29","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00702-003-0822-z","article-title":"Rett syndrome \u2013 an update.","volume":"110","author":"Jellinger","year":"2003","journal-title":"J Neural Transm."},{"key":"B30","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.neuroscience.2010.07.010","article-title":"Monoamine deficits in the brain of methylCpG binding protein 2 null mice suggest the involvement of the cerebral cortex in early stages of Rett syndrome.","volume":"170","author":"Santos","year":"2010","journal-title":"Neuroscience."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2017.00061","article-title":"Analysis of the serotonergic system in a mouse model of Rett syndrome reveals unusual upregulation of serotonin receptor 5b.","volume":"10","author":"Vogelgesang","year":"2017","journal-title":"Front Mol Neurosci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.neuropharm.2018.10.018","article-title":"Rescue of prepulse inhibition deficit and brain mitochondrial dysfunction by pharmacological stimulation of the central serotonin receptor 7 in a mouse model of CDKL5 Deficiency Disorder.","volume":"144","author":"Vigli","year":"2019","journal-title":"Neuropharmacology."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107746","article-title":"Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder.","volume":"167","author":"Fuchs","year":"2020","journal-title":"Neuropharmacology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1165\/rcmb.2013-0372OC","article-title":"Effect of Sarizotan, a 5-HT 1a and D2-like receptor agonist, on respiration in three mouse models of Rett syndrome.","volume":"50","author":"Abdala","year":"2014","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/B978-0-444-64012-3.00024-1","article-title":"The psychopharmacology of autism spectrum disorder and Rett syndrome.","volume":"165","author":"Persico","year":"2019","journal-title":"Handb Clin Neurol."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.825063","article-title":"Excitation and inhibition imbalance in Rett syndrome.","volume":"16","author":"Li","year":"2022","journal-title":"Front Neurosci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1038\/npp.2014.136","article-title":"Improvement of the Rett syndrome phenotype in a Mecp2 mouse model upon treatment with levodopa and a Dopa-decarboxylase inhibitor.","volume":"39","author":"Szczesna","year":"2014","journal-title":"Neuropsychopharmacology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-3-642-45106-5_9","article-title":"BDNF and synaptic plasticity, cognitive function, and dysfunction.","volume":"220","author":"Lu","year":"2014","journal-title":"Handb Exp Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10571-017-0510-4","article-title":"BDNF: A key factor with multipotent impact on brain signaling and synaptic plasticity.","volume":"38","author":"Kowia\u0144ski","year":"2018","journal-title":"Cell Mol Neurobiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"9947","DOI":"10.1073\/pnas.1309426111","article-title":"\u03b22Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome.","volume":"111","author":"Mellios","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B41","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.neuropharm.2013.03.024","article-title":"BDNF deregulation in Rett syndrome.","volume":"76","author":"Li","year":"2014","journal-title":"Neuropharmacology."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113202","article-title":"CDKL5 deficiency in adult glutamatergic neurons alters synaptic activity and causes spontaneous seizures via TrkB signaling.","volume":"42","author":"Zhu","year":"2023","journal-title":"Cell Rep."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2021.113245","article-title":"Quercetin alleviates chronic unpredictable mild stress-induced depressive-like behaviors by promoting adult hippocampal neurogenesis via FoxG1\/CREB\/ BDNF signaling pathway.","volume":"406","author":"Ma","year":"2021","journal-title":"Behav Brain Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuroscience.2016.03.056","article-title":"The role of Insulin-Like Growth Factor 1 (IGF-1) in brain development, maturation and neuroplasticity.","volume":"325","author":"Dyer","year":"2016","journal-title":"Neuroscience."},{"key":"B45","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrd4417","article-title":"Righting Rett syndrome with IGF1.","volume":"13","author":"Bray","year":"2014","journal-title":"Nat Rev Drug Discov."},{"key":"B46","doi-asserted-by":"publisher","first-page":"9941","DOI":"10.1073\/pnas.1311685111","article-title":"Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome.","volume":"111","author":"Castro","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00020","article-title":"Insulin-like growth factor-1 downregulates the phosphorylation of FXYD1 and rescues behavioral deficits in a mouse model of Rett syndrome.","volume":"14","author":"Yuan","year":"2020","journal-title":"Front Neurosci."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4161\/rdis.27265","article-title":"A role for metabolism in Rett syndrome pathogenesis.","volume":"1","author":"Justice","year":"2013","journal-title":"Rare Dis."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.170216","article-title":"Rett syndrome: A neurological disorder with metabolic components.","volume":"8","author":"Kyle","year":"2018","journal-title":"Open Biol."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044218","article-title":"MeCP2 is an epigenetic factor that links DNA methylation with brain metabolism.","volume":"24","author":"Vuu","year":"2023","journal-title":"Int J Mol Sci."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133317","article-title":"Loss of mevalonate\/cholesterol homeostasis in the brain: A focus on autism spectrum disorder and Rett syndrome.","volume":"20","author":"Segatto","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0887-8994(02)00399-5","article-title":"Brain glucose metabolism in Rett syndrome.","volume":"27","author":"Villemagne","year":"2002","journal-title":"Pediatr Neurol."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030396","article-title":"The GABA polarity shift and bumetanide treatment: Making sense requires unbiased and undogmatic analysis.","volume":"11","author":"Ben-Ari","year":"2022","journal-title":"Cells."},{"key":"B54","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.tins.2017.07.001","article-title":"NKCC1 chloride importer antagonists attenuate many neurological and psychiatric disorders.","volume":"40","author":"Ben-Ari","year":"2017","journal-title":"Trends Neurosci."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-01945635-9","article-title":"Early alterations in a mouse model of Rett syndrome: The GABA developmental shift is abolished at birth.","volume":"9","author":"Lozovaya","year":"2019","journal-title":"Sci Rep."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/j.1528-1157.1997.tb01486.x","article-title":"Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity.","volume":"38","author":"Monaghan","year":"1997","journal-title":"Epilepsia."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1111\/j.1528-1167.2007.01182.x","article-title":"Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy.","volume":"48","author":"Pieribone","year":"2007","journal-title":"Epilepsia."},{"key":"B58","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/epi.13705","article-title":"Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures.","volume":"58","author":"Sperling","year":"2017","journal-title":"Epilepsia."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00213-017-4649-y","article-title":"A randomized controlled trial of ganaxolone in posttraumatic stress disorder.","volume":"234","author":"Rasmusson","year":"2017","journal-title":"Psychopharmacology."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s00213-018-4892-x","article-title":"Effect of ganaxolone in patients with posttraumatic stress disorder.","volume":"235","author":"Kawada","year":"2018","journal-title":"Psychopharmacology."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12887","article-title":"Effects of open-label, adjunctive ganaxolone on persistent depression despite adequate antidepressant treatment in postmenopausal women.","volume":"81","author":"Dichtel","year":"2020","journal-title":"J Clin Psychiatry."},{"key":"B62","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1474-4422(22)00077-1","article-title":"Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: Results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.","volume":"21","author":"Knight","year":"2022","journal-title":"Lancet Neurol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/15357597221125238","article-title":"Ganaxolone: A new treatment for CDKL5 deficiency disorder.","volume":"22","author":"Vossler","year":"2022","journal-title":"Epilepsy Curr."},{"key":"B64","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.biopsych.2016.03.1045","article-title":"N-Methyl-D-aspartate receptors, ketamine, and Rett syndrome: Something special on the road to treatments?","volume":"79","author":"Katz","year":"2016","journal-title":"Biol Psychiatry."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.657714","article-title":"Repurposing ketamine in depression and related disorders: Can this enigmatic drug achieve success?","volume":"15","author":"Carboni","year":"2021","journal-title":"Front Neurosci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/00002826-200403000-00003","article-title":"Multicenter, Open-label, trial of sarizotan in parkinson disease patients with levodopainduced dyskinesias (the SPLENDID study).","volume":"27","author":"Olanow","year":"2004","journal-title":"Clin Neuropharmacol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson\u2019s disease: A double-blind placebo-controlled trial.","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov Disord."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1152\/japplphysiol.00889.2013","article-title":"A selective 5-HT 1a receptor agonist improves respiration in a mouse model of Rett syndrome.","volume":"115","author":"Levitt","year":"2013","journal-title":"J Appl Physiol."},{"key":"B69","first-page":"51","author":"Sheikh","year":"2014","journal-title":"Pre-clinical study of NLX-101 for the treatment of apnoeas in two mouse models of Rett syndrome."},{"key":"B70","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.resp.2010.08.017","article-title":"The role of serotonin in respiratory function and dysfunction.","volume":"174","author":"Hilaire","year":"2010","journal-title":"Respir Physiol Neurobiol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/pds.3312","article-title":"Off-label antidepressant use in children and adolescents compared with young adults: Extent and level of evidence.","volume":"21","author":"Czaja","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.04.1006","article-title":"Off-label drug use in children and adolescents with depressive disorder.","volume":"21","author":"Lai","year":"2018","journal-title":"Value Health."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1097\/00004583-20011000000011","article-title":"LongTerm sertraline treatment of children and adolescents with obsessive-compulsive disorder.","volume":"40","author":"Cook","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"B74","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1089\/cap.2006.16.103","article-title":"Long-term sertraline treatment of children and adolescents with major depressive disorder.","volume":"16","author":"Rynn","year":"2006","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1089\/cap.2022.0048","article-title":"Effects of long-term sertraline use on pediatric growth and development: The sertraline pediatric registry for the evaluation of safety (SPRITES).","volume":"33","author":"Kolitsopoulos","year":"2023","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40263-022-00896-3","article-title":"Lorcaserin for Dravet syndrome: A potential advance over fenfluramine?","volume":"36","author":"Bialer","year":"2022","journal-title":"CNS Drugs."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16923","article-title":"Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder.","volume":"62","author":"Devinsky","year":"2021","journal-title":"Epilepsia."},{"key":"B78","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.neuron.2005.12.027","article-title":"The Disease Progression of Mecp2 Mutant Mice Is Affected by the Level of BDNF Expression.","volume":"49","author":"Chang","year":"2006","journal-title":"Neuron."},{"key":"B79","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.pediatrneurol.2016.05.010","article-title":"Pharmacologic treatment of rett syndrome with glatiramer acetate.","volume":"61","author":"Djukic","year":"2016","journal-title":"Pediatr Neurol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.pediatrneurol.2016.11.006","article-title":"A potential life-threatening reaction to glatiramer acetate in Rett syndrome.","volume":"68","author":"Nissenkorn","year":"2017","journal-title":"Pediatr Neurol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"14230","DOI":"10.1073\/pnas.1206093109","article-title":"Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome.","volume":"109","author":"Deogracias","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B82","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1093\/hmg\/ddv218","article-title":"Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington\u2019s disease by preventing p75 NTR up-regulation and astrocyte-mediated inflammation.","volume":"24","author":"Miguez","year":"2015","journal-title":"Hum Mol Genet."},{"key":"B83","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.bbr.2014.03.046","article-title":"Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid \u03b2induced memory impairment.","volume":"268","author":"Fukumoto","year":"2014","journal-title":"Behav Brain Res."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01655-7","article-title":"Fingolimod in children with Rett syndrome: The FINGORETT study.","volume":"16","author":"Naegelin","year":"2021","journal-title":"Orphanet J Rare Dis."},{"key":"B85","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ecl.2012.04.010","article-title":"The insulin-like growth factors and growth disorders of childhood.","volume":"41","author":"Backeljauw","year":"2012","journal-title":"Endocrinol Metab Clin North Am."},{"key":"B86","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1073\/pnas.1311141111","article-title":"Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome.","volume":"111","author":"Khwaja","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B87","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/acn3.533","article-title":"Placebo-controlled crossover assessment of mecasermin for the treatment of Rett syndrome.","volume":"5","author":"O\u2019Leary","year":"2018","journal-title":"Ann Clin Transl Neurol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jns.2008.12.003","article-title":"NNZ-2566: A Gly\u2013Pro\u2013Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke.","volume":"278","author":"Bickerdike","year":"2009","journal-title":"J Neurol Sci."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106704","article-title":"Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome.","volume":"114","author":"Neul","year":"2022","journal-title":"Contemp Clin Trials."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","article-title":"Trofinetide for the treatment of Rett syndrome: A randomized phase 3 study.","volume":"29","author":"Neul","year":"2023","journal-title":"Nat Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/1570159X15666170703101816","article-title":"Statins and the brain: More than lipid lowering agents?","volume":"17","author":"Fracassi","year":"2018","journal-title":"Curr Neuropharmacol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/ng.2714","article-title":"A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome.","volume":"45","author":"Buchovecky","year":"2013","journal-title":"Nat Genet."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.22409","article-title":"Lovastatin fails to improve motor performance and survival in methyl-CpG-binding protein2-null mice.","volume":"5","author":"Villani","year":"2016","journal-title":"Elife."},{"key":"B94","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/adc.2004.051375","article-title":"Corticosteroids in the management of the paediatric epilepsies.","volume":"90","author":"Gupta","year":"2005","journal-title":"Arch Dis Child."},{"key":"B95","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s40263-022-00921-5","article-title":"CDKL5 deficiency disorder-related epilepsy: A review of current and emerging treatment.","volume":"36","author":"Hong","year":"2022","journal-title":"CNS Drugs."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/hmg\/ddr602","article-title":"Pharmacological interference with the glucocorticoid system influences symptoms and lifespan in a mouse model of Rett syndrome.","volume":"21","author":"Braun","year":"2012","journal-title":"Hum Mol Genet."},{"key":"B97","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.neuropharm.2012.05.048","article-title":"Neonatal exposure to low dose corticosterone persistently modulates hippocampal mineralocorticoid receptor expression and improves locomotor\/exploratory behaviour in a mouse model of Rett syndrome.","volume":"68","author":"De Filippis","year":"2013","journal-title":"Neuropharmacology."},{"key":"B98","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1093\/hmg\/ddac067","article-title":"Pregnenolone-methyl-ether enhances CLIP170 and microtubule functions improving spine maturation and hippocampal deficits related to CDKL5 deficiency.","volume":"31","author":"Barbiero","year":"2022","journal-title":"Hum Mol Genet."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010068","article-title":"Loss of CDKL5 causes synaptic GABAergic defects that can be restored with the neuroactive steroid pregnenolone-methyl-ether.","volume":"24","author":"De Rosa","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B100","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jpeds.2005.10.037","article-title":"Rett syndrome in Australia: A review of the epidemiology.","volume":"148","author":"Laurvick","year":"2006","journal-title":"J Pediatr."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1212\/01.wnl.0000291011.54508.aa","article-title":"Specific mutations in Methyl-CpG-Binding Protein 2 confer different severity in Rett syndrome.","volume":"70","author":"Neul","year":"2008","journal-title":"Neurology."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1086\/320109","article-title":"MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin.","volume":"68","author":"Trappe","year":"2001","journal-title":"Am J Hum Genet."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.624290","article-title":"The molecular functions of MeCP2 in Rett syndrome pathology.","volume":"12","author":"Sharifi","year":"2021","journal-title":"Front Genet."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1289","article-title":"14q12q13.2 microdeletion syndrome: Clinical characterization of a new patient, review of the literature, and further evidence of a candidate region for CNS anomalies.","volume":"8","author":"Ponzi","year":"2020","journal-title":"Mol Genet Genomic Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1425038\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T04:53:26Z","timestamp":1722228806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1425038\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":104,"alternative-id":["10.3389\/fmed.2024.1425038"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1425038","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"article-number":"1425038"}}